Pamela Ohashi

Ohashi obtained her BSc in Biology from York University in 1982.[1]

She received her PhD from the University of Toronto Department of Immunology in 1988. Her graduate supervisor was Tak Wah Mak.[1][2]

In her undergraduate studies at York University, Ohashi did wet lab research in the laboratories of James Friesen, John Heddle, and Ron Pearlman.[1]

Following an interest in immunology, she pursued a PhD in Tak Mak’s lab at Princess Margaret Hospital, graduating in 1988.[1][2]

Ohashi conducted post-doctoral research with Rolf Zinkernagel and Hans Hengartner at the University of Zurich until 1991.[1][2][3]

In 1992, Ohashi established a research program at Princess Margaret Hospital, where she is now a Senior Scientist.[4]

Ohashi is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.[3][5]

At Princess Margaret Cancer Centre, Ohashi is Co-Director of the Campbell Family Institute for Breast Cancer Research, and Director of the Cancer Immune Therapy Program.

Her achievements resulted in her appointment as Canada Research Chair in Autoimmunity and Tumour Immunity.[6]

Ohashi undertook a fourth year undergraduate research project with Dr Ron Pearlman on genomic analysis of Tetrahymena repetitive sequences.[1][7]

In her PhD research on T Cell Receptors (TCR), Ohashi found that expression of beta chain cDNA was essential for the expression of a functional TCR/CD3 complex on the cell surface. This complex was shown to be responsible for mediating signal transduction via specific stimulation of the TCR of Jurkat cells.[8] She created mouse lines with transgenic T cells expressing rearranged TCR genes and showed evidence supporting the model that commitment to certain T cell lineages occurs prior to the rearrangement of the composite receptor genes.[9]

Ohashi’s early work focused on understanding basic mechanisms of T cell tolerance versus activation. She was a pioneer in showing conclusively that thymocyte selection is based on an affinity/avidity model.[2][10][11] She was also the first to demonstrate that self-reactive peripheral T cells can remain in a naïve state in the T cell repertoire; a concept that has become widely known as T cell “ignorance”.[2][12]  

This has led to Ohashi’s current approach in understanding how to manipulate and improve cytotoxic T cells to enhance the immune response against cancer.[1] She demonstrated that ignorant T cells could be activated against tumours and showed that altering the molecular programming of dendritic cells can alter the steady state and promote T cell activation in the absence of conventional dendritic cell maturation signals.[2][13][14][15] This is a novel way to break T cell tolerance in vivo and provides important insights into potential mechanisms of autoimmunity.[2][16]

Ohashi directs the translational program of Princess Margaret Cancer Centre's Cancer Immune Therapy Program, designing and running clinical trials using novel immune therapeutic approaches to treat cancer patients.[4] Ohashi was key investigator on the first Phase I clinical trial to use adoptive cell therapy for ovarian cancer.[17]

2018: Robert L Noble Prize[3][18]

2015: Member of the Board of Directors of the Society for Immunotherapy of Cancer[3][19]

2014: Hardy Cinader Award[2]

2011: CSI Investigator Award[20]

2006: Fellow of the Royal Society of Canada[21]

2003: Pharmingen Investigator Award[22]

1998: William E. Rawls Award[1][2]

Chair of the AACR Immunotherapy Steering committee[3]

Founding Senior Editor: Cancer Immunology Research[3]